Durvalumab in Endometrial Cancer: DUO-E Trial Updates

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss recent updates from the DUO-E trial, highlighting key efficacy and safety data that led to the FDA’s approval of durvalumab for endometrial cancer while examining how this new indication influences treatment strategies for advanced or recurrent cases.

EP: 1.Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 2.Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP: 3.Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP: 4.Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP: 5.Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

EP: 6.Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP: 7.Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP: 8.Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP: 9.Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

EP: 10.Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

EP: 11.Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights

Now Viewing

EP: 12.Durvalumab in Endometrial Cancer: DUO-E Trial Updates

Video content above is prompted by the following:

Briefly comment on recent data updates presented for the DUO-E trial and offer insights into the recently approved FDA indication for durvalumab in endometrial cancer.
Briefly comment on key takeaways from efficacy and safety data leading to the new approval.
How does the approved indication for durvalumab affect your treatment approach for advanced or recurrent endometrial cancer?